The Bahrain AI biotech deal with SandboxAQ will create $1B in biotech assets, driving innovation and positioning Bahrain as a Gulf biotech hub.
Bahrain AI biotech deal sovereign wealth fund, Mumtalakat, has signed a landmark agreement with SandboxAQ, a US-based artificial intelligence and quantum technology firm, to develop biotech assets worth over $1 billion for the Gulf nation.
Also Read: Aramco’s Wa’ed Ventures Leads $10M Bet on US Biotech Firm
The partnership will leverage SandboxAQ’s quantitative AI tools to discover drug targets and design novel therapeutics, strengthening Bahrain’s role as a regional biotech innovation hub. A joint research committee will lead a three-year programme to build new intellectual property in life sciences and digital healthcare.
Shaikh Abdulla bin Khalifa Al Khalifa, CEO of Mumtalakat, said the agreement aligns with Bahrain’s AI biotech deal strategy to diversify its economy and expand into high-value health sectors powered by AI and advanced technology.
In May, Mumtalakat reported its largest profit to date, BD 363 million ($963 million) for 2024, reversing a BD 497 million loss from the previous year. The fund now manages approximately $18 billion in assets, cementing its position among the Gulf’s most forward-thinking investors.
The initiative mirrors Saudi Aramco’s collaboration with SandboxAQ, announced earlier this year, to deploy AI in energy and sustainability projects.
By partnering with SandboxAQ, the Bahrain AI biotech deal aims to fast-track biotech research, attract global investors, and position itself as a leading AI-driven economy in the MENA region.
